Log in to your Inderes Free account to see all free content on this page.

Vimian Group

28.85 SEK

-1.54 %

Less than 1K followers

VIMIAN

NASDAQ Stockholm

Health Care Providers

Health Care

Overview

Financials & Estimates

Ownership

Dividend

Investor consensus

-1.54 %

+1.41 %

+8.62 %

-4.91 %

-1.87 %

-25.91 %

+1.69 %

-

-63.17 %

Vimian Group is a group operating in animal health. The company, through its subsidiaries, delivers pharmaceuticals and technical solutions to veterinarians, laboratories and pet owners. The products include, for example, pharmaceuticals with associated clinical research and digital platforms for veterinary clinics. The company operates on a global level with headquarters in Stockholm.

Market cap

15.27B SEK

Turnover

11.09M SEK

Revenue

EBIT %

P/E

Dividend yield-%

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

17.7.

2026

Interim report Q2'26

22.10.

2026

Interim report Q3'26

11.2.

2027

Annual report '26

All

Webcasts

Press releases

ShowingAll content types

Regulatory press release4/29/2026, 2:00 PM

Press release from the Annual General Meeting in Vimian Group AB (publ) on 29 April 2026

Vimian Group, Audiocast, Q1'26

Webcast4/29/2026, 7:00 AM

Vimian Group, Audiocast, Q1'26

Regulatory press release4/29/2026, 5:45 AM

Vimian’s Interim Report for the first quarter of 2026

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Press release4/21/2026, 8:10 AM

Invitation to Vimian’s Interim Report for the first quarter of 2026

Regulatory press release3/19/2026, 6:45 AM

Notice of Annual General Meeting in Vimian Group AB (publ)

Regulatory press release3/19/2026, 6:30 AM

Vimian publishes Annual Report and Sustainability Report for 2025

Regulatory press release3/13/2026, 7:00 AM

Vimian Group AB (publ) appoints Lotta Lundaas Head of Medtech and member of the Vimian Group management team

Vimian Group, Audiocast, Q4'25

Webcast2/12/2026, 8:00 AM

Vimian Group, Audiocast, Q4'25

Regulatory press release2/12/2026, 6:45 AM

Vimian’s year-end report for 2025

Press release2/2/2026, 9:00 AM

Invitation to Vimian’s year-end report for 2025

Regulatory press release1/12/2026, 6:45 AM

Vimian Group AB (publ) announces departure of Head of Specialty Pharma segment

Regulatory press release12/30/2025, 4:30 PM

Change in the number of shares and votes in Vimian

Press release12/23/2025, 7:05 AM

Vimian acquires I-Vet to strengthen its companion animal diagnostics offering

Regulatory press release12/22/2025, 8:30 PM

Vimian has resolved to issue and repurchase additional class D shares, class E1 2025 shares, class E2 2025 shares, and class E3 2025 shares as part of its long-term incentive program 2025

Regulatory press release11/28/2025, 4:30 PM

Change in the number of shares and votes in Vimian

Regulatory press release11/24/2025, 6:15 AM

Vimian Group AB (publ) appoints Alireza Tajbakhsh as CEO

Regulatory press release10/27/2025, 6:00 AM

Vimian has resolved to issue and repurchase class D shares, class E1 2025 shares, class E2 2025 shares, and class E3 2025 shares as part of its long-term incentive program 2025

Vimian Group, Audiocast, Q3'25

Webcast10/22/2025, 7:00 AM

Vimian Group, Audiocast, Q3'25

Regulatory press release10/22/2025, 5:45 AM

Vimian’s Interim Report for the third quarter of 2025

Press release10/13/2025, 8:00 AM

Invitation to Vimian’s Interim Report for the third quarter of 2025

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.